We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of innovative-targeted therapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cel... Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of innovative-targeted therapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively. Its most advanced products are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia. Show more
Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral...
Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy PR Newswire NEW YORK, March 26, 2024 Potential...
Actinium Pharmaceuticals Launches Actinium-225 Focused Strategic Initiative to Leverage Proprietary Cyclotron Based Manufacturing Technology to Address Growing Market Demand PR Newswire NEW YORK...
Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial at the 2024 Tandem Meetings |...
Actinium Highlights Improved Survival with Iomab-B in TP53 Positive Relapsed Refractory Acute Myeloid Leukemia Patients in the SIERRA Trial and Other Presentations at the 2024 Tandem Meetings |...
Actinium Announces Acceptance of Five Abstracts for Presentation at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® PR Newswire NEW YORK, Jan. 2...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.54 | -17.5199089875 | 8.79 | 9.28 | 7.2 | 333334 | 8.67294422 | CS |
4 | -0.95 | -11.5853658537 | 8.2 | 9.8599 | 7.2 | 583558 | 8.79401474 | CS |
12 | 2.08 | 40.2321083172 | 5.17 | 9.8599 | 5 | 355220 | 7.9956606 | CS |
26 | 1.26 | 21.0350584307 | 5.99 | 9.8599 | 4 | 271095 | 6.82396854 | CS |
52 | -1.83 | -20.154185022 | 9.08 | 9.8599 | 4 | 237576 | 7.09757094 | CS |
156 | -0.14 | -1.89445196211 | 7.39 | 15.12 | 4 | 299438 | 8.09215698 | CS |
260 | 6.7513 | 1353.77982755 | 0.4987 | 15.12 | 0.1506 | 1835186 | 1.40647987 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions